Conmed Corporation Stock Downgraded by Piper Sandler
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy CNMD?
Source: seekingalpha
- Rating Downgrade Impact: Piper Sandler downgraded Conmed (CNMD) from Overweight to Neutral, citing a lack of catalysts to spark investor interest, leading to a stock decline on Tuesday that reflects market concerns about the company's future growth.
- Demand Slowdown Analysis: Analyst Matt O'Brien noted that while Conmed's AirSeal robotic solution did not completely implode after Intuitive Surgical (ISRG) launched a competing product, poor messaging and execution missteps have negatively impacted the stock for two years.
- Market Outlook Comparison: O'Brien concurrently upgraded Tandem Diabetes (TNDM) to Overweight, indicating that he sees better prospects in other SMID-cap MedTech companies, which further exacerbates the negative outlook for Conmed.
- Lack of Catalysts: Despite Conmed's attractive valuation and M&A capacity, the analyst believes there are currently no clear catalysts to turn the company's situation around, reflecting a pessimistic sentiment regarding its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNMD
Wall Street analysts forecast CNMD stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 36.800
Low
41.00
Averages
50.00
High
55.00
Current: 36.800
Low
41.00
Averages
50.00
High
55.00
About CNMD
CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Conmed Corporation Stock Downgraded by Piper Sandler
- Rating Downgrade Impact: Piper Sandler downgraded Conmed (CNMD) from Overweight to Neutral, citing a lack of catalysts to spark investor interest, leading to a stock decline on Tuesday that reflects market concerns about the company's future growth.
- Demand Slowdown Analysis: Analyst Matt O'Brien noted that while Conmed's AirSeal robotic solution did not completely implode after Intuitive Surgical (ISRG) launched a competing product, poor messaging and execution missteps have negatively impacted the stock for two years.
- Market Outlook Comparison: O'Brien concurrently upgraded Tandem Diabetes (TNDM) to Overweight, indicating that he sees better prospects in other SMID-cap MedTech companies, which further exacerbates the negative outlook for Conmed.
- Lack of Catalysts: Despite Conmed's attractive valuation and M&A capacity, the analyst believes there are currently no clear catalysts to turn the company's situation around, reflecting a pessimistic sentiment regarding its future growth potential.
See More
CONMED Shares Enter Oversold Territory
- Oversold Signal: CONMED Corp (CNMD) saw its RSI drop to 29.95 during Tuesday's trading, indicating the stock has entered oversold territory, suggesting that the recent heavy selling may be exhausting, prompting investors to look for buying opportunities.
- Price Fluctuation: CNMD shares hit a low of $38.42, with the current trading price at $38.46, highlighting significant volatility compared to its 52-week low of $35.37 and high of $63.69, reflecting market sentiment.
- Market Comparison: In contrast to the S&P 500 ETF (SPY) RSI of 43.4, CNMD's oversold condition may attract bullish investors, especially during potential shifts in market sentiment.
- Investment Opportunity: Given the oversold signal, investors might consider buying CNMD shares as they rebound, aiming to capitalize on potential recovery opportunities and enhance portfolio returns.
See More
CONMED's Stock Decline and Uncertain Outlook
- Lackluster Revenue Growth: CONMED's annualized revenue growth of 5.1% over the past two years falls short of its five-year trend, indicating a slowdown in demand that may reflect changing consumer preferences, raising concerns for investors.
- Distribution Channel Limitations: With $1.37 billion in revenue over the past 12 months, CONMED struggles as a small player in the healthcare sector, where lack of scale hampers trust-building with customers and limits market potential.
- Unfavorable Revenue Projections: Wall Street analysts forecast a 1.3% decline in CONMED's revenue over the next 12 months, a stark contrast to its previous five-year annualized growth of 9.8%, suggesting demand headwinds that could negatively impact valuations.
- Limited Investment Appeal: Although CONMED trades at a forward P/E of 10.6x with a share price of $45.91, the potential upside appears limited compared to the risks, leading investors to seek more attractive alternatives in the market.
See More
CONMED Corporation Q4 2025 Earnings Call Insights
- Sales Growth: CONMED reported total sales of $373.2 million for Q4 2025, reflecting a year-over-year increase of 7.9%, with full-year sales reaching $1.375 billion, indicating stable growth potential in the medical device market.
- Strategic Shift: The company announced its exit from gastroenterology product lines, which is expected to improve long-term consolidated gross margins by approximately 80 basis points, demonstrating a focus on higher-growth business areas.
- Supply Chain Improvement: In sports medicine, CONMED reported back order values and SKU counts at a three-year low, indicating significant progress in resolving supply chain constraints, which is expected to further drive future performance.
- Future Outlook: Management is guiding for 2026 revenue between $1.345 billion and $1.375 billion, with adjusted EPS between $4.30 and $4.45, reflecting confidence in future growth and a commitment to ongoing investments.
See More
CONMED (CNMD) Q4 2025 Earnings Call Transcript
See More
CONMED (CNMD) Experiences Oversold Conditions
CONMED Corp Trading Update: Shares of CONMED Corp (CNMD) have entered oversold territory with an RSI reading of 29.5, indicating potential exhaustion of recent selling pressure.
Current Share Price and Performance: The stock traded as low as $38.83, with a current price of $38.99, while its 52-week range is between $38.83 and $76.34.
Investor Sentiment: Bullish investors may view the low RSI as an opportunity to consider buying, anticipating a potential rebound in the stock's performance.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
See More
Conmed Corporation Stock Downgraded by Piper Sandler
- Rating Downgrade Impact: Piper Sandler downgraded Conmed (CNMD) from Overweight to Neutral, citing a lack of catalysts to spark investor interest, leading to a stock decline on Tuesday that reflects market concerns about the company's future growth.
- Demand Slowdown Analysis: Analyst Matt O'Brien noted that while Conmed's AirSeal robotic solution did not completely implode after Intuitive Surgical (ISRG) launched a competing product, poor messaging and execution missteps have negatively impacted the stock for two years.
- Market Outlook Comparison: O'Brien concurrently upgraded Tandem Diabetes (TNDM) to Overweight, indicating that he sees better prospects in other SMID-cap MedTech companies, which further exacerbates the negative outlook for Conmed.
- Lack of Catalysts: Despite Conmed's attractive valuation and M&A capacity, the analyst believes there are currently no clear catalysts to turn the company's situation around, reflecting a pessimistic sentiment regarding its future growth potential.
See More
CONMED Shares Enter Oversold Territory
- Oversold Signal: CONMED Corp (CNMD) saw its RSI drop to 29.95 during Tuesday's trading, indicating the stock has entered oversold territory, suggesting that the recent heavy selling may be exhausting, prompting investors to look for buying opportunities.
- Price Fluctuation: CNMD shares hit a low of $38.42, with the current trading price at $38.46, highlighting significant volatility compared to its 52-week low of $35.37 and high of $63.69, reflecting market sentiment.
- Market Comparison: In contrast to the S&P 500 ETF (SPY) RSI of 43.4, CNMD's oversold condition may attract bullish investors, especially during potential shifts in market sentiment.
- Investment Opportunity: Given the oversold signal, investors might consider buying CNMD shares as they rebound, aiming to capitalize on potential recovery opportunities and enhance portfolio returns.
See More
CONMED's Stock Decline and Uncertain Outlook
- Lackluster Revenue Growth: CONMED's annualized revenue growth of 5.1% over the past two years falls short of its five-year trend, indicating a slowdown in demand that may reflect changing consumer preferences, raising concerns for investors.
- Distribution Channel Limitations: With $1.37 billion in revenue over the past 12 months, CONMED struggles as a small player in the healthcare sector, where lack of scale hampers trust-building with customers and limits market potential.
- Unfavorable Revenue Projections: Wall Street analysts forecast a 1.3% decline in CONMED's revenue over the next 12 months, a stark contrast to its previous five-year annualized growth of 9.8%, suggesting demand headwinds that could negatively impact valuations.
- Limited Investment Appeal: Although CONMED trades at a forward P/E of 10.6x with a share price of $45.91, the potential upside appears limited compared to the risks, leading investors to seek more attractive alternatives in the market.
See More
CONMED Corporation Q4 2025 Earnings Call Insights
- Sales Growth: CONMED reported total sales of $373.2 million for Q4 2025, reflecting a year-over-year increase of 7.9%, with full-year sales reaching $1.375 billion, indicating stable growth potential in the medical device market.
- Strategic Shift: The company announced its exit from gastroenterology product lines, which is expected to improve long-term consolidated gross margins by approximately 80 basis points, demonstrating a focus on higher-growth business areas.
- Supply Chain Improvement: In sports medicine, CONMED reported back order values and SKU counts at a three-year low, indicating significant progress in resolving supply chain constraints, which is expected to further drive future performance.
- Future Outlook: Management is guiding for 2026 revenue between $1.345 billion and $1.375 billion, with adjusted EPS between $4.30 and $4.45, reflecting confidence in future growth and a commitment to ongoing investments.
See More
CONMED (CNMD) Q4 2025 Earnings Call Transcript
See More
CONMED (CNMD) Experiences Oversold Conditions
CONMED Corp Trading Update: Shares of CONMED Corp (CNMD) have entered oversold territory with an RSI reading of 29.5, indicating potential exhaustion of recent selling pressure.
Current Share Price and Performance: The stock traded as low as $38.83, with a current price of $38.99, while its 52-week range is between $38.83 and $76.34.
Investor Sentiment: Bullish investors may view the low RSI as an opportunity to consider buying, anticipating a potential rebound in the stock's performance.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
See More
